Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 11
2003 7
2004 9
2005 9
2006 10
2007 9
2008 5
2009 9
2010 6
2011 6
2012 7
2013 7
2014 11
2015 11
2016 12
2017 6
2018 9
2019 6
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

139 results
Results by year
Filters applied: . Clear all
Page 1
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J. Aymerich MS, et al. Among authors: Fernandez-Ruiz J. Biochem Pharmacol. 2018 Nov;157:67-84. doi: 10.1016/j.bcp.2018.08.016. Epub 2018 Aug 17. Biochem Pharmacol. 2018. PMID: 30121249 Free article. Review.
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J. López-Sendón Moreno JL, et al. Among authors: Fernandez Ruiz J. J Neurol. 2016 Jul;263(7):1390-400. doi: 10.1007/s00415-016-8145-9. Epub 2016 May 9. J Neurol. 2016. PMID: 27159993 Clinical Trial.
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways.
del Río C, Navarrete C, Collado JA, Bellido ML, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Pollastro F, Appendino G, Calzado MA, Cantarero I, Muñoz E. del Río C, et al. Among authors: Fernandez-Ruiz J. Sci Rep. 2016 Feb 18;6:21703. doi: 10.1038/srep21703. Sci Rep. 2016. PMID: 26887982 Free PMC article.
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.
Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E. Díaz-Alonso J, et al. Among authors: Fernandez-Ruiz J. Sci Rep. 2016 Jul 19;6:29789. doi: 10.1038/srep29789. Sci Rep. 2016. PMID: 27430371 Free PMC article.
Preface: Why a Special Issue on cannabinoid research in Spain?
Fernández-Ruiz J. Fernández-Ruiz J. Biochem Pharmacol. 2018 Nov;157:1-7. doi: 10.1016/j.bcp.2018.10.018. Epub 2018 Oct 21. Biochem Pharmacol. 2018. PMID: 30352232 No abstract available.
Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders.
Navarro G, Morales P, Rodríguez-Cueto C, Fernández-Ruiz J, Jagerovic N, Franco R. Navarro G, et al. Among authors: Fernandez-Ruiz J. Front Neurosci. 2016 Sep 13;10:406. doi: 10.3389/fnins.2016.00406. eCollection 2016. Front Neurosci. 2016. PMID: 27679556 Free PMC article. Review.
139 results
Jump to page
Feedback